Neurocognitive impairment in HIV-infected individuals remains a significant problem despite antiretroviral therapy. There is a critical need for surrogate markers that can be used to predict cognitive impairment and to monitor the effects of antiretroviral, or neuroprotective therapy in HIV-infected individuals.
Objectives and Goals
- Assist in the development and monitoring of surrogate markers for HIV-associated neurocognitive disorders (HAND)
- To provide mentorship and consultation for Neuro-AIDS researchers in the development of clinically useful surrogate markers for HAND and to validate these as predictive and associative markers for cognitive impairment and as surrogate markers for therapeutic effectiveness
An additional task of the Surrogate Markers Core will be to assist in the development of small molecule therapeutics by providing consultation on pharamcokinetic/pharmacodynamic considerations for drug development, and conducting pharmacokinetic and analysis of potential drugs and drug metabolites.